Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07588100 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy

A Phase 1 study, sponsored by Hoffmann-La Roche.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target

NCT07588100: Recruiting Phase 1 study, sponsored by Hoffmann-La Roche.

NCT07588100 is a Phase 1 study that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07588100, a Phase 1 study, is actively recruiting participants, sponsored by Hoffmann-La Roche.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target

Study Summary

This study will assess the safety, tolerability, and pharmacokinetics (PK) of intravitreal (IVT) injections of RO7663498 in participants with diabetic retinopathy (DR).

Interventions

  • DRUG RO7663498

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2026-06-18
Est. Completion 2027-12-30
Phase Phase 1
Hoffmann-La Roche

909 total trials

What NCT07588100 shows while recruiting

NCT07588100 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).

The record links to 0 conditions, and to 1 intervention - of which RO7663498 is the first listed.

NCT07588100 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07588100 about?

NCT07588100 is a clinical study titled "A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy". This study will assess the safety, tolerability, and pharmacokinetics (PK) of intravitreal (IVT) injections of RO7663498 in participants with diabetic retinopathy (DR).

What is the current status of trial NCT07588100?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2026-06-18. Estimated completion is 2027-12-30.

What interventions are being tested in trial NCT07588100?

The interventions under investigation include: RO7663498 (DRUG).

Who is sponsoring clinical trial NCT07588100?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07588100's enrollment target sits among peer trials

30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07588100, the US trial registry maintained by the National Library of Medicine. NCT07588100 (small enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.